Kringle Pharma (4884) · TargetRestated
Resumption of Acute Kidney Injury Development After Securing Funding
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Temporary Suspension and Resumption Plan for Acute Kidney Injury Development Due to Funding ConstraintsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「We have temporarily suspended development for this disease for financial reasons, but plan to resume it once sufficient financial resources become available.」
急性腎障害の開発を資金面から一旦中止し、資金的余裕の確保後に再開する計画を引き続き示している。 - FY2020First statedAnnual report
「We have temporarily suspended development for this disease for financial reasons, but plan to resume it once sufficient financial resources become available.」
Following the U.S. Phase Ia/Ib trial, development was temporarily suspended for financial reasons, with plans to resume after sufficient funding is secured.